The jackpot cancer immunotherapy ambitions of AstraZeneca stumbled in July with the failure of a closely watched clinical trial in newly diagnosed lung cancer. Friday, the Anglo-Swedish drugmaker attempts a recovery with positive results from a new study, also in lung cancer, but aimed at a niche group of patients.
AstraZeneca still trails cancer immunotherapy leaders Merck and Bristol-Myers Squibb, but staking a claim in lung cancer marks progress.
About the Author Reprints
